Shenfu decoction preparation and its preparation method and application

Abstract

The application discloses a Shengfu decoction and a preparation method and application thereof, and a traditional Chinese medicine composition, which comprises ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum, and the ratio of the ginseng, the aconite, the salvia miltiorrhiza and the platycodon grandiflorum is 3:2:(3-4):(2-3) in mass fraction. The traditional Chinese medicine composition can effectively prevent and treat the symptoms of silicosis fibrosis. The pharmacology of the traditional Chinese medicine composition is that the ginseng has the effects of being sweet, slightly bitter and slightly warm, and can greatly supplement primordial qi, restore pulse and fix loss of consciousness, supplement the spleen and the lung, produce saliva and nourish blood, and calm the nerves and improve intelligence; the aconite is pungent, sweet, highly hot and toxic, and has the effects of restoring yang and saving from danger, supplementing fire and assisting yang, and dispelling cold and relieving pain; the two are matched to reduce toxicity and increase efficacy; the salvia miltiorrhiza can relieve lung fibrosis by eliminating oxygen free radicals, resisting lipid peroxidation, inhibiting collagen repair imbalance and resisting inflammation; and the platycodon grandiflorum has the effects of resisting inflammation, resisting viruses, protecting the liver, regulating immunity and resisting tumors.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of treating silicosis fibrosis, and particularly relates to a Shengfu decoction preparation and a preparation method and application thereof. BACKGROUND

[0002] Silicosis is a disease caused by long-term inhalation of free silicon dioxide (SiO2) dust in the lung, which is mainly characterized by diffuse fibrosis of lung tissue, and is also one of the occupational diseases with the highest incidence. It is the main cause of labor loss of workers in a dust environment. The main pathological changes are lung fibrosis caused by lung interstitial cell proliferation and excessive deposition of extracellular matrix. Silicosis has existed for a long time in China. In the Shang and Zhou dynasties, people engaged in ceramics, mining and smelting. In the Song Dynasty, there is a record in “Tan Yuan” that “Jia Guoshan Cai Shi people, the end of the stone hurt the lung, the lung is hot and many people die”. Later generations of physicians also have the pathogenic theory of “gold and stone dry heat” and “gold and stone, dry and toxic”. For patients with silicosis fibrosis, acetylcysteine tablets, pirfenidone tablets and nintedanib can be taken for treatment, but the western medicine treatment has defects such as high price, large side effects and treating symptoms not the root cause, so it is urgent to develop traditional Chinese medicine compound preparation for treating silicosis fibrosis. SUMMARY

[0003] In view of the deficiencies of the prior art, the purpose of the present application is to provide a traditional Chinese medicine composition.

[0004] Another purpose of the present application is to provide the use of the traditional Chinese medicine composition in the preparation of a drug for treating lung fibrosis.

[0005] A traditional Chinese medicine composition comprises ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum, and the ratio of ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum is 3:2:(3-4):(2-3) by mass fraction.

[0006] A preparation method of a Shengfu decoction preparation, wherein the traditional Chinese medicine composition is water-extracted to obtain the Shengfu decoction preparation.

[0007] In the above technical solution, the traditional Chinese medicine composition is water-extracted to obtain the Shengfu decoction preparation.

[0008] The above-mentioned Chinese medicine composition is used for preparing a drug for treating lung tissue fibrosis. The Chinese medicine composition can effectively prevent and treat the symptoms of silicosis fibrosis. The pharmacology of the Chinese medicine composition is as follows: ginseng has the effects of being sweet, slightly bitter and slightly warm, and can greatly supplement primordial qi, restore pulse, supplement the spleen and the lung, produce saliva and nourish blood, and calm the mind and improve intelligence; aconite has the effects of being pungent, sweet, extremely hot, toxic, restoring yang, supplementing fire and assisting yang, and dispelling cold and relieving pain, and the two can be combined to reduce toxicity and increase efficacy; salvia miltiorrhiza can relieve lung fibrosis by eliminating oxygen free radicals, resisting lipid peroxidation, inhibiting collagen repair imbalance and resisting inflammation; and platycodon grandiflorum has the effects of resisting inflammation, resisting viruses, protecting the liver, regulating immunity and resisting tumors. The combination of the above-mentioned medicines can jointly play the effect of warming and tonifying heart yang, and can warm and tonify the kidney and the lung, activate blood and resolve phlegm, and has obvious effects on treating silicosis fibrosis. BRIEF DESCRIPTION OF DRAWINGS

[0009] Figure 1 Fig. 1 is a morphological diagram of lung tissue of Wistar rats in a model control group, a silicosis model group, a Shenfu Decoction plus-minus preparation prevention group and a Shenfu Decoction plus-minus preparation treatment group;

[0010] Figure 2 Fig. 2 is a statistical diagram of lung coefficient index changes of Wistar rats in the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group;

[0011] Figure 3 Fig. 3 is a HE staining diagram of lung tissue of Wistar rats in the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group;

[0012] Figure 4 Fig. 4 is a HE staining diagram of liver tissue and a HE staining diagram of kidney tissue of Wistar rats in a model control 8-week group, a silicosis model 8-week group, a Shenfu Decoction plus-minus preparation prevention group and a Shenfu Decoction plus-minus preparation treatment group;

[0013] Figure 5 Fig. 5 is a statistical diagram of white blood cell numbers in bronchial alveolar lavage fluid of Wistar rats in the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group;

[0014] Figure 6 Fig. 6 is a Wright-Giemsa staining diagram of macrophages of Wistar rats in the model control 8-week group, the silicosis model 8-week group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group;

[0015] Figure 7 Fig. 7 is an immunohistochemical staining diagram of lung tissue alpha-SMA of Wistar rats in the model control 8-week group, the silicosis model 8-week group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group;

[0016] Figure 8The Western blotting and alpha-SMA protein statistical chart of the model control 8-week group, the silicosis model 8-week group, the Shenfu decoction plus-minus preparation prevention group and the Shenfu decoction plus-minus preparation treatment group of Wistar rats are shown in the figure. DETAILED DESCRIPTION

[0017] The technical solutions of the present application are further described in detail below in combination with the drawings and examples.

[0018] The Wright-Giemsa staining solution is purchased from Zhuhai Baisu Biotechnology Company, and the Wright-Giemsa staining solution includes Wright-Giemsa staining solution A and Wright-Giemsa staining solution B.

[0019] The loading buffer is purchased from Beijing Zhuangmeng International Biological Gene Technology Co., Ltd.

[0020] In the following examples, the method for preparing 4% paraformaldehyde fixing solution includes: placing 2 g of paraformaldehyde powder in a 50 mL centrifuge tube, adding 50 mL of normal saline, vortexing to completely dissolve the paraformaldehyde powder, obtaining 4% paraformaldehyde fixing solution, and storing the 4% paraformaldehyde fixing solution in a 4℃ refrigerator.

[0021] In the drawings, ** indicates P<0.01, *** indicates P<0.01, and **** indicates P<0.0001 compared with the model control group with the same feeding time; ## indicates P<0.01, ### indicates P<0.001, and #### indicates P<0.0001 compared with the silicosis model 8-week group.

[0022] In the drawings, n is the sample size, and F value is the probability value, and when F>0.05, it represents that the difference between groups is not significant.

[0023] The concentration of sodium chloride in the normal saline used in the following examples is 0.9 g / mL.

[0024] The Shenfu decoction plus-minus preparation used in the following examples is sealed with a sealing film and stored in a 4℃ refrigerator for sealed storage for standby, and the storage time can reach 2 weeks.

[0025] Example 1

[0026] A preparation method of a Shenfu decoction plus-minus preparation includes the following steps:

[0027] The ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum are weighed and placed in water for decoction, and the water is boiled at 180℃ (stove fire) until boiling, then the temperature is adjusted to 80℃ (small fire) to maintain gentle boiling, and the decoction is continued to concentrate until the Shenfu decoction plus-minus preparation is obtained, wherein the mass ratio of ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum is 3:2:4:3, the mass fraction of ginseng, the volume fraction of water and the volume fraction of Shenfu decoction plus-minus preparation are 15:900:200, and the unit of mass fraction is g and the unit of volume fraction is mL.

[0028] SiO2 suspension: 2 g of SiO2 particles were weighed on a balance and placed in a mortar for grinding, baked at 80°C for 4 hours, and after baking, the SiO2 particles were placed in a 50 mL centrifuge tube, 40 mL of normal saline was measured with a graduated cylinder and added to the centrifuge tube, and the mixture was shaken well to obtain a SiO2 suspension (the concentration of SiO2 in the SiO2 suspension was 50 mg / mL). The SiO2 suspension was sealed with sealing film and stored in a 4°C refrigerator for standby use.

[0029] SPF level healthy adult Wistar rats were selected, and the weight of each Wistar rat was (200±20) g. All Wistar rats were bred in a pathogen-free environment in the experimental animal center of Huabei Science and Technology College. According to the random number table method, 12 groups of experimental animals were divided, and each group of experimental animals contained 6 Wistar rats.

[0030] The 12 groups of experimental animals were divided as follows:

[0031] Model control group: Wistar rats were taken daily by gavage with 50 μL of normal saline, and were normally fed daily. After X weeks of feeding, the Wistar rats were sacrificed. Among them, the model control group was divided into model control 1 week group, model control 2 week group, model control 4 week group and model control 8 week group according to the feeding time (gavage time). Each group was continuously gavaged every day, and the number and X were shown in Table 1.

[0032] Table 1

[0033]

[0034]

[0035] Silicosis model group: Wistar rats were taken by intubation in the oropharynx-trachea, and 1 mL of SiO2 suspension was perfused for dusting. After dusting, the Wistar rats were normally fed daily, and after Y weeks of feeding, the Wistar rats were sacrificed. Among them, the silicosis model group was divided into silicosis model 1 week group, silicosis model 2 week group, silicosis model 4 week group and silicosis model 8 week group according to the feeding time, and the number and Y were shown in Table 2.

[0036] Table 2

[0037] Silicosis model group Number Y week Silicosis model 1 week group Si1 1 week Silicosis model 2 week group Si2 2 weeks Silicosis model 4 week group Si4 4 weeks Silicosis model 8 week group Si8 8 weeks

[0038] Shenfu Decoction plus-minus preparation prevention group: Shenfu Decoction plus-minus preparation prepared in Example 1 was used to gavage Wistar rats, and the mass of Shenfu Decoction plus-minus preparation prepared in Example 1 gavaged per 1 kg of body weight of Wistar rats was 6.25 g. After 48 h of gavage of Shenfu Decoction plus-minus preparation prepared in Example 1, 1 mL of SiO2 suspension was used to conduct dusting by intubation in the oropharynx-trachea of Wistar rats. After dusting, Wistar rats were normally fed every day, and after 8 weeks of feeding, Wistar rats were sacrificed. Among them, the Shenfu Decoction plus-minus preparation prevention group was numbered as Pre.

[0039] Shenfu Decoction plus-minus preparation treatment group: Wistar rats were intubated in the oropharynx-trachea, and 1 mL of SiO2 suspension was used to conduct dusting. After 48 h of dusting, Shenfu Decoction plus-minus preparation prepared in Example 1 was used to gavage Wistar rats every day, and the mass of Shenfu Decoction plus-minus preparation prepared in Example 1 gavaged per 1 kg of body weight of Wistar rats was W. The body weight of Wistar rats was weighed every 7 days, and the dosage of Shenfu Decoction plus-minus preparation prepared in Example 1 was adjusted according to the change of body weight. After 8 weeks of continuous feeding, Wistar rats were sacrificed. Among them, the Shenfu Decoction plus-minus preparation treatment group was divided into Shenfu Decoction plus-minus preparation high-dose treatment group, Shenfu Decoction plus-minus preparation medium-dose treatment group and Shenfu Decoction plus-minus preparation low-dose treatment group according to the dosage of Shenfu Decoction plus-minus preparation gavaged, and the number and W were shown in Table 3.

[0040] Table 3

[0041]

[0042]

[0043] Animal experiment:

[0044] (1) Experimental solvent:

[0045] 3% pentobarbital sodium solution: 3 g of pentobarbital sodium powder was weighed on a balance, and the pentobarbital sodium powder was poured into a 200 mL volumetric flask, 100 mL of normal saline was added, and the mixture was dissolved to obtain a 3 g / mL pentobarbital sodium solution, which was stored at 4°C in a refrigerator for standby use.

[0046] (2) Experimental operation:

[0047] The Wistar rats in the above-mentioned experimental groups were respectively over-anesthetized with 3% sodium pentobarbital solution, and after the Wistar rats were killed, they were fixed on the operating table, the fur from the neck to the xiphoid was wiped with a cotton ball soaked in normal saline, a longitudinal incision was made from the neck to the manubrium, and the trachea and lungs were exposed layer by layer, a T-shaped incision was made at the trachea, a cannula was inserted, and a thin wire was used for fixation. 5 mL of normal saline was sucked into a 5 mL syringe and lung lavage was performed through the cannula, and the lung lavage was performed three times until the lung alveoli turned white. The three times of lung alveolar lavage fluid (15 mL) was placed in a 15 mL centrifuge tube and mixed well, filtered with double-layer sterile gauze, and the bronchoalveolar lavage fluid (BALF) was obtained. The BALF was placed in a centrifuge tube and stored in an ice box.

[0048] The lungs, liver and kidneys of the Wistar rats were completely separated, the surrounding connective tissue was carefully removed, the cannula was cut off and recovered, the lungs were washed with normal saline, the lungs were photographed, and the color, luster, texture, elasticity, lung congestion and swelling degree of the bilateral lungs were observed with the naked eye, and the general image of the animal was saved. The right lower lobe of the lung was taken for lung histopathological observation, and the remaining lobes of the lung were respectively placed in different centrifuge tubes and stored in a-80°C refrigerator for Western blot analysis.

[0049] Figure 1 The lung tissue of the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group Wistar rats was taken and shaped, and the lung tissue was taken and shaped. Figure 1 It can be seen that the surface of the lung tissue of the model control group is smooth, and no obvious granular nodules are present; the lung tissue surface of the silicosis model 1 week group, the silicosis model 2 week group, the silicosis model 4 week group and the silicosis model 8 week group all have granular nodules, and with the extension of the feeding time, the granular nodules are more obvious; the lung tissue surface of the Shenfu Decoction plus-minus preparation prevention group can see granular nodules, but the range of granular nodules is smaller than that of the silicosis model 8 week group; compared with the silicosis model 8 week group, the lung tissue surface of the Shenfu Decoction plus-minus preparation treatment group has granular nodules, but the range of granular nodules is smaller than that of the silicosis model 8 week group. Compared with the Shenfu Decoction plus-minus preparation high-dose treatment group, the Shenfu Decoction plus-minus preparation medium-dose treatment group and the Shenfu Decoction plus-minus preparation low-dose treatment group, the lungs of the Shenfu Decoction plus-minus preparation high-dose treatment group are pink, the texture is soft, and the granular nodules are smaller than those of the Shenfu Decoction plus-minus preparation low-dose treatment group and the Shenfu Decoction plus-minus preparation medium-dose treatment group. These experimental results show that after the administration of Shenfu Decoction plus-minus preparation, the fibrosis symptoms of rats are alleviated, and Shenfu Decoction has the potential to prevent and treat silicosis fibrosis.

[0050] After the lungs were washed with normal saline, they were dried with filter paper, and the wet weight of the lungs was weighed on an electronic balance. The lung coefficient was calculated, and the lung coefficient = (lung wet weight / Wistar rat body weight) x 100%. Figure 2The lung coefficient index change statistical graph of the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group Wistar rats, compared with the model control group, the lung coefficient of the Wistar rats in the silicosis model group was significantly increased, and after treatment with Shenfu Decoction plus-minus preparation, the lung coefficient of the Wistar rats in the Shenfu Decoction plus-minus preparation treatment group was reduced in a dose-dependent manner.

[0051] Further explore the pathological morphology of Wistar rats in each experimental animal group, immerse the right lower lobe of the lung in the 4% paraformaldehyde fixing solution prepared in advance, fix it in the 4°C refrigerator for 48 hours, paraffin embedding, slicing (the thickness of the slice is 4μm), and observe the Wistar rat lung tissue slice dyed with hematoxylin-eosin (HE), as shown in Figure 3 Figure 3 The HE staining diagram of the lung tissue of the Wistar rats in the model control group, the silicosis model group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group, as shown in Figure 3 It can be known from

[0052] Immerse the liver and kidney in the 4% paraformaldehyde fixing solution prepared in advance, fix it in the 4°C refrigerator for 48 hours, paraffin embedding, slicing (the thickness of the slice is 4μm), and observe the Wistar rat liver slice and kidney tissue slice dyed with HE, Figure 4 The HE staining diagram of the liver tissue and the kidney tissue of the Wistar rats in the model control 8-week group, the silicosis model 8-week group, the Shenfu Decoction plus-minus preparation prevention group and the Shenfu Decoction plus-minus preparation treatment group, Figure 4 The first row and the third row of the liver tissue HE results, as shown in Figure 4 It can be known from Figure 4 ​The second row and the fourth row of the kidney tissue HE results, the results show that the model control 8 weeks group, the Shenfu decoction plus-minus preparation prevention group, the Shenfu decoction plus-minus preparation treatment group Wistar rat glomerular structure is clear, the renal tubule collecting duct is arranged closely and regularly, the renal tubular epithelial cells are arranged regularly and the basement membrane is complete, and no inflammatory cell infiltration is found, the above results show that the Shenfu decoction plus-minus preparation has no toxicity to Wistar rats.

[0053] Take 1 mL bronchoalveolar lavage fluid (BALF) and dilute 20 times with normal saline, take 10 μL of the diluted bronchoalveolar lavage fluid and add it to the bovine baugh cell counting plate, under the optical microscope, count the total number of white blood cells in the four large squares in the four corners of the bovine baugh cell counting plate, and the cell counting formula is: cell number / mL=(total number of white blood cells / 4)×dilution multiple×10 4 mL. Figure 5 The white blood cell number histogram of the bronchoalveolar lavage fluid of the model control group, the silicosis model group, the Shenfu decoction plus-minus preparation prevention group and the Shenfu decoction plus-minus preparation treatment group Wistar rats, from Figure 5 It can be seen that compared with the model control group, the total number of white blood cells in the bronchoalveolar lavage fluid of the silicosis model group Wistar rats induced by silicon dioxide is significantly increased, and different doses of Shenfu decoction plus-minus preparation treatment group can significantly reduce the total number of white blood cells in the bronchoalveolar lavage fluid of the silicosis model group Wistar rats induced by silicon dioxide, and in the Shenfu decoction plus-minus preparation treatment group, the medium dose Shenfu decoction plus-minus preparation treatment group and the high dose Shenfu decoction plus-minus preparation treatment group can better reduce the total number of white blood cells in the bronchoalveolar lavage fluid.

[0054] Further, the remaining 14 mL BALF is placed in a 4℃ centrifuge for centrifugation at 12000g for 10min, and after centrifugation, a cell precipitate is obtained, the cell precipitate is resuspended with 0.5mL pre-cooled (4℃) normal saline, and after sufficient blowing, a cell suspension is obtained, 5μL of the cell suspension is taken and smeared on a clean glass slide, after smearing, a fixed area is circled with a wax pen, and after it is slightly dried, it is fixed with 4% paraformaldehyde fixing solution for 20min, and then Wright-Giemsa staining is performed: according to the operation instruction of Wright-Giemsa staining reagent, 0.5mL of Wright-Giemsa staining solution A is added dropwise to the smear for 20s, then 1mL of Wright-Giemsa staining solution B is added dropwise to the Wright-Giemsa staining solution A, and the Wright-Giemsa staining solution A and the Wright-Giemsa staining solution B are mixed by blowing with an ear bulb, and after staining for 1min, the glass slide is rinsed with PBS buffer (PH=7) and then with tap water, and after rinsing, it is placed in a fume hood for air drying, and the dried glass slide is observed under an optical microscope for the number of macrophages.

[0055] Figure 6The Wright-Giemsa staining chart of macrophages of the model control 8-week group, the silicosis model group, the Shenfu Decoction modified preparation prevention group and the Shenfu Decoction modified preparation treatment group is shown in Fig. 1. Figure 6 It can be seen that, compared with the model control 8-week group, the number of macrophages of the Wistar rats in the silicosis model group increased significantly with the extension of feeding time, and compared with the silicosis model group, the number of macrophages of the Wistar rats in the Shenfu Decoction modified preparation prevention group decreased, and the number of macrophages of the Wistar rats in the Shenfu Decoction modified preparation treatment group of different doses decreased significantly.

[0056] Figure 7 The α-SMA expression in the lung tissue of the Wistar rats of the model control 8-week group, the silicosis model 8-week group, the Shenfu Decoction modified preparation prevention group and the Shenfu Decoction modified preparation treatment group is shown in Fig. 4. Figure 7 It can be seen that, α-smooth muscle actin (α-SMA) has a large number of positive expressions in the lung tissue of the Wistar rats of the silicosis model 8-week group, and the expression intensity and area are particularly obvious, while the positive expression range and intensity of the model control 8-week group, the Shenfu Decoction modified preparation prevention group and the Shenfu Decoction modified preparation treatment group are obviously weaker than those of the silicosis model 8-week group.

[0057] The lung tissue in the centrifuge tube is cut into 80mg small pieces, 600uL tissue cell lysate and 6uL protease inhibitor are added, homogenized, then lysed on ice for 40 minutes to obtain the lysate. The lysate is centrifuged at 12,000xg for 10 minutes at 4℃, and the supernatant (i.e. α-SMA protein) is taken. The α-SMA protein is diluted with ultrapure water to obtain a diluent, and the concentration of the diluent is 10ug / uL. The diluent is mixed with the loading buffer, and the volume ratio of the diluent to the loading buffer is 4:1. The mixture is heated at 100℃ for 10min, and then cooled. The mixture is subjected to Western blot analysis, and β-actin is used as an internal reference. The results are shown in Fig. 5. Figure 8 Figure 8 The Western blot and α-SMA protein statistical chart of the Wistar rats of the model control 8-week group, the silicosis model 8-week group, the Shenfu Decoction modified preparation prevention group and the Shenfu Decoction modified preparation treatment group are shown in Fig. 6. Figure 8 ​It can be known that the expression of α-SMA protein in lung tissue of Wistar rats in the silicosis model 8-week group was obviously higher than that in the model control 8-week group by Western blot. Compared with the silicosis model 8-week group, the expression of α-SMA protein in lung tissue of Wistar rats in the Shenfu decoction plus-minus preparation prevention group and the Shenfu decoction plus-minus preparation treatment group were obviously decreased, wherein the expression of α-SMA protein in the Shenfu decoction plus-minus preparation high-dose treatment group was close to the expression of a-SMA protein in the model control 8-week group. α-SMA protein is a marker protein of myofibroblasts, which represents the degree of pulmonary fibrosis to some extent. The decrease of α-SMA protein indicates that the degree of fibrosis is improved. Therefore, the Shenfu decoction plus-minus preparation high-dose treatment group can significantly alleviate the silicosis fibrosis of rats, which indicates that the Shenfu decoction plus-minus preparation can effectively treat pulmonary fibrosis.

[0058] The above has made an exemplary description of the present application, it should be explained that, without departing from the core of the present application, any simple modification, change or other equivalent replacement which can not cost the creative labor of the person skilled in the art falls into the protection scope of the present application.

Claims

1. A traditional Chinese medicine composition for treating fibrosis of lung tissue, characterized in that, It is composed of ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum, and the ratio of ginseng, aconite, salvia miltiorrhiza and platycodon grandiflorum is 3:2:(3~4):(2~3) by mass fraction.

2. A method for preparing a Shenfu Decoction Modified Preparation, characterized in that, The traditional Chinese medicine composition of claim 1 is water-extracted to obtain a modified Shenfu decoction.

3. Use of the traditional Chinese medicine composition of claim 1 in the preparation of a drug for treating pulmonary fibrosis.

Images